echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Hot new year! Another company's IPO is expected to fill the gap of skin disease treatment

    Hot new year! Another company's IPO is expected to fill the gap of skin disease treatment

    • Last Update: 2020-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the past few decades, the treatment of many immune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and COPD, has made remarkable progress Although many of these methods can be used in the treatment of skin diseases, there is still a lack of attention and innovation in the field of skin disease treatment On October 21, arcutis biotherapeutics, a California based biomedical company, announced the completion of round C financing of US $94.5 million So far, it has completed more than $160 million in financing In less than two months, arcutis recently announced plans to raise $100 million in an IPO Arcutis may not be well known, but it has previously worked with Hengrui pharmaceuticals and AstraZeneca Arcutis company was founded in 2016, mainly engaged in the research and development of medical skin topical products It uses the frontier technology of inflammation and immunology to develop the potential "best in class" therapy for the biological target that has been verified At present, according to the information on its website, there are three compounds under development under its R & D pipeline, namely arq-151, arq-154 and arq-252 Arq-151 and arq-154 are small molecular inhibitors of PDE4 PDE4 is an intracellular enzyme that can increase the production of pro-inflammatory mediators and reduce the production of anti-inflammatory mediators Arq-151 cream for external use is currently being used in clinical trials to treat patients with plaque psoriasis and atopic dermatitis It has shown long-term efficacy and good tolerance in the previous stage 2B clinical trial of plaque psoriasis Arcutis said that the phase 2B study of arq-151 in patients with atopic dermatitis is expected to start in the first half of 2020 ARQ-154 is a topical foam preparation It is almost the same as ARQ-151 It is currently being used in clinical trials to treat seborrheic dermatitis Arcutis has initiated a phase 2B clinical trial to evaluate arq-154 in the treatment of seborrheic dermatitis The raised funds will be mainly used to promote the clinical trials of arq-151 and arq-154 to the next stage Arq-252 is a selective inhibitor of Jak1 Inhibition of Jak1 has been shown to treat a variety of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn's disease and atopic dermatitis Arq-252 is currently developing treatments for eczema, vitiligo, and alopecia areata Arcutis believes that arq-252 can effectively treat inflammatory diseases without causing adverse hematopoietic reactions usually associated with JAK2 inhibition Arcutis R & D pipeline (photo source: arcutis biotherapeutics official website) Atopic dermatitis is a serious chronic, recurrent skin disease The main symptoms were pruritus, dry skin and inflammation It can appear anywhere in the body Although the new treatment for atopic dermatitis has been on the market for many years, there are still many dermatologists who have not benefited from it They were treated with traditional therapy, but it didn't work Some of these therapies have no specific target, or have serious safety and tolerance problems Dermatologists and patients are in urgent need of innovative local treatment methods, which can directly improve local skin efficacy and reduce systemic safety risks Arcutis is to fill this gap Arcutis believes that taking advantage of development opportunities in other areas of medicine, especially inflammation and immunology, will probably solve the unmet medical needs in the treatment of skin diseases We also look forward to the successful listing of arcutis and, with the help of capital, bringing more effective therapies to patients around the world as soon as possible.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.